Laboratory Corp. of America Holdings

Laboratory Corporation of America Holdings is a life sciences company engaged in providing clinical laboratory and end-to-end drug development services. The company reports its business in two segments: LabCorp Diagnostics, which provides a menu of specialty testing through an integrated network of primary and specialty laboratories across the U.S., supported by an information technology system, logistics, local labs providing testing, and also provides patient access points located throughout the U.S.; and Covance Drug Development, which provides end-to-end drug development, medical device and diagnostic solutions from early-stage research to clinical development and commercial market access.
  • TickerLH
  • ISINUS50540R4092
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

2 directors sold

Two Directors at Laboratory Corp Of America Holdings sold 7,891 shares at 176.750USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules....

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

Debbie Wang

Morningstar | Diagnostic Lab Industry Aims to Improve Medicare Reimbursement With Addition of Hospital Labs

Now that the diagnostic industry has begun to see the full and more-dramatic-than-expected effect of reductions in the Medicare clinical lab fee schedule that were rolled out in 2018, the industry is fighting back more strenuously. Most recently, the industry has prompted the introduction of a bipartisan bill, the Laboratory Access for Beneficiaries Act, in the House. While this doesn’t shift our fair value estimates for narrow-moat LabCorp or Quest Diagnostics, it should ratchet up pressure on the higher-cost hospital-based labs to comply with reimbursement reporting requirements contained in...

Debbie Wang

Diagnostic Lab Industry Aims to Improve Medicare Reimbursement With Addition of Hospital Labs

Now that the diagnostic industry has begun to see the full and more-dramatic-than-expected effect of reductions in the Medicare clinical lab fee schedule that were rolled out in 2018, the industry is fighting back more strenuously. Most recently, the industry has prompted the introduction of a bipartisan bill, the Laboratory Access for Beneficiaries Act, in the House. While this doesn’t shift our fair value estimates for narrow-moat LabCorp or Quest Diagnostics, it should ratchet up pressure on ...

Laboratory Corporation of America Holdings: Update to credit analysis

LabCorp's credit profile is supported by the company's significant market presence and moderate leverage.

Moody's: LabCorp's Divestiture of Food Solutions Business is Credit Positive

Moody's Investors Service commented that the announcement by Laboratory Corporation of America Holdings ("LabCorp") to divest its Food Solutions business for $670 million is a credit positive. There is no impact on LabCorp's Baa2 ratings or stable outlook. For additional inform...

Laboratory Corporation of America Holdings: LabCorp's divestiture of Food Solutions business is credit positive

LabCorp's divestiture of Covance Food Solutions business will help in further reducing leverage.

Laboratory Corporation of America Holdings: Update to credit analysis

CORPORATES CREDIT OPINION 13 October 2017 Update RATINGS Laboratory Corporation of America Holdings Domicile Burlington, North Carolina, United States Long Term Rating Baa2 Type Senior Unsecured - Dom Curr Outlook Stable Please see the  ratings section  at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts J

Moody's: Proposed Medicare Lab Rate Cuts Would be Credit Negative for LabCorp

Announcement: Moody's: Proposed Medicare Lab Rate Cuts Would be Credit Negative for LabCorp. Global Credit Research- 26 Sep 2017. New York, September 26, 2017-- Moody's Investors Service commented on the 22 September announcement that The Centers for Medicare and Medicaid Services released proposed rates for the Clinical Laboratory Fee Schedule.

Debbie Wang

Morningstar | Diagnostic Lab Industry Aims to Improve Medicare Reimbursement With Addition of Hospital Labs

Now that the diagnostic industry has begun to see the full and more-dramatic-than-expected effect of reductions in the Medicare clinical lab fee schedule that were rolled out in 2018, the industry is fighting back more strenuously. Most recently, the industry has prompted the introduction of a bipartisan bill, the Laboratory Access for Beneficiaries Act, in the House. While this doesn’t shift our fair value estimates for narrow-moat LabCorp or Quest Diagnostics, it should ratchet up pressure on the higher-cost hospital-based labs to comply with reimbursement reporting requirements contained in...

Debbie Wang

Diagnostic Lab Industry Aims to Improve Medicare Reimbursement With Addition of Hospital Labs

Now that the diagnostic industry has begun to see the full and more-dramatic-than-expected effect of reductions in the Medicare clinical lab fee schedule that were rolled out in 2018, the industry is fighting back more strenuously. Most recently, the industry has prompted the introduction of a bipartisan bill, the Laboratory Access for Beneficiaries Act, in the House. While this doesn’t shift our fair value estimates for narrow-moat LabCorp or Quest Diagnostics, it should ratchet up pressure on ...

Debbie Wang

Morningstar | Diagnostic Lab Industry Aims to Improve Medicare Reimbursement With Addition of Hospital Labs

Now that the diagnostic industry has begun to see the full and more-dramatic-than-expected impact of reductions in the Medicare clinical lab fee schedule that were rolled out in 2018, the industry is fighting back more strenuously. Most recently, the industry has prompted introduction of a bipartisan bill, the Laboratory Access for Beneficiaries Act, in the House. While this doesn’t shift our fair value estimates for narrow-moat LabCorp or Quest Diagnostics, it should rachet up pressure on the higher-cost hospital-based labs to comply with reimbursement reporting requirements contained in the ...

Debbie Wang

Diagnostic Lab Industry Aims to Improve Medicare Reimbursement With Addition of Hospital Labs

Now that the diagnostic industry has begun to see the full and more-dramatic-than-expected impact of reductions in the Medicare clinical lab fee schedule that were rolled out in 2018, the industry is fighting back more strenuously. Most recently, the industry has prompted introduction of a bipartisan bill, the Laboratory Access for Beneficiaries Act, in the House. While this doesn’t shift our fair value estimates for narrow-moat LabCorp or Quest Diagnostics, it should rachet up pressure on the h...

Debbie Wang

Morningstar | PAMA Cuts Apply Steady Pressure in 2019, but Could Ease in 2021

As a leading independent diagnostic laboratory, LabCorp participates in a highly attractive duopoly that offers bright prospects as healthcare moves toward reformed payment models, despite near-term Medicare headwinds. Even though hospitals still dominate the $72 billion diagnostic market, LabCorp has carved out a significant slice of the pie through serial acquisitions. The addition of Covance's drug-development expertise offers LabCorp an avenue to monetize its large patient database.Just as importantly, LabCorp has single-mindedly pursued greater efficiency, which translates to an ability t...

2 directors sold

Two Directors at Laboratory Corp Of America Holdings sold 7,891 shares at 176.750USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules....

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

MarketLine Department

Quest Diagnostics Incorporated - Strategy, SWOT and Corporate Finance Report

Summary Quest Diagnostics Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Quest Diagnostics Incorporated (Quest or 'the company') provides diagnostic information services. The company offers diagnostic testing service and clinical trials testing service to physicians and patients through its laboratories and its patient service centers. It also prov...

MarketLine Department

Biocept, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Biocept, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Biocept, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlig...

MarketLine Department

Veracyte, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Veracyte, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Veracyte, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highl...

MarketLine Department

Tenet Healthcare Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Tenet Healthcare Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Tenet Healthcare Corporation since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its compe...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

As higher lows continue within a broader YTD sideways consolidation, the S&P 500 is poised to retest the 2,790-2,800 horizontal resistance level that we have highlighted in previous reports. While we continue to expect the broad YTD consolidation to continue, below we highlight additional factors that lead to our overall constructive outlook: • XLF bouncing off critical support with authority. We have voiced our concern regarding a potential breakdown below $26.50 on the XLF and the negative implications that it would have on the broad market. We have also noted a failure to break down woul...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch